IHC 2021 | The role of glutamatergic receptor activation in migraine
Anna Andreou, PhD, King’s College London, London, UK, talks on the role of glutamate as a treatment target for migraine. Glutamate involvement in migraine pathophysiology has been reported for many years. Dr Andreou explains that glutamate is the main excitatory neurotransmitter in the trigeminal pathway, which drives and modulates activation of the pain pathway. This interview took place during the International Headache Congress 2021.
Disclosures
Honoraria for educational purposes from AbbVie, Allergan, Eli Lilly, eNeura, Zenith Scientific.
Honoraria for advisory purposes from Allergan, Eli Lilly, eNeura, Neuresta, Zenith Scientific.
R&D funding from eNeura, Eli Lilly.
Sponsorship for educational purposes from Allergan, ATI, Eli Lilly, eNeura, Novartis.
Board member of GSConsulting, Neuresta.
